AXIAL BIOTHERAPEUTICS
Axial Therapeutics is a clinical stage biopharmaceutical company harnessing the gut-brain axis to develop novel Central Nervous System (CNS) Therapeutics to improve the quality of life for people with CNS diseases and disorders.
AXIAL BIOTHERAPEUTICS
Industry:
Biopharma Biotechnology Medical Pharmaceutical
Founded:
2016-01-01
Address:
Woburn, Massachusetts, United States
Country:
United States
Website Url:
http://www.axialtx.com
Total Employee:
11+
Status:
Active
Contact:
617-874-5260
Email Addresses:
[email protected]
Total Funding:
110.9 M USD
Technology used in webpage:
U.S. Server Location Ninja Forms
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Eidos Therapeutics
Eidos Therapeutics is a clinical-stage biotech company developing novel, genetically targeted therapies to improve the lives of patients.
KSQ Therapeutics
KSQ Therapeutics is using CRISPR technology within a powerful drug discovery engine to enable high-confidence drug development.
Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company committed to developing therapy for the treatment of hypertension.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
PhaseBio Pharmaceuticals
PhaseBio is a clinical-stage biopharmaceutical company that develops drugs for cardiovascular diseases, endocrine, and metabolic disorders.
Current Advisors List
Current Employees Featured
Founder
Investors List
Seventure Partners
Seventure Partners investment in Series C - Axial Biotherapeutics
Corundum Systems Biology
Corundum Systems Biology investment in Series C - Axial Biotherapeutics
OneVentures
OneVentures investment in Series C - Axial Biotherapeutics
Longwood Fund
Longwood Fund investment in Series C - Axial Biotherapeutics
Autism Impact Fund
Autism Impact Fund investment in Series C - Axial Biotherapeutics
Domain Associates
Domain Associates investment in Series C - Axial Biotherapeutics
Taiho Ventures
Taiho Ventures investment in Series C - Axial Biotherapeutics
UTokyo Innovation Platform
UTokyo Innovation Platform investment in Series C - Axial Biotherapeutics
Taiho Ventures
Taiho Ventures investment in Series B - Axial Biotherapeutics
Domain Associates
Domain Associates investment in Series B - Axial Biotherapeutics
Official Site Inspections
http://www.axialtx.com Semrush global rank: 5.21 M Semrush visits lastest month: 1.49 K
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Axial Biotherapeutics"
Join the Team - Axial Therapeutics
Discovering and developing targeted small molecule therapeutics to treat serious diseases and conditions by leveraging the microbiome’s role in human health. Axial Therapeutics is a …See details»
Open Positions - Axial Therapeutics
Your Career Starts With Axial Axial Therapeutics is a clinical-stage biopharmaceutical company dedicated to discovering and developing targeted small molecule therapeutics to treat serious …See details»
Leadership | Axial Therapeutics
Dr. Oalmann joined Axial in July 2018, and brings nearly 30 years of experience experience in medicinal chemistry leadership with a successful record of delivering development candidates …See details»
Axial Therapeutics, Inc. Information - RocketReach
Axial Therapeuticsâ„¢ is a clinical-stage biopharmaceutical company focused on the discovery and development of gut-restricted, small molecule therapeutics for central nervous system (CNS) …See details»
Axial Therapeutics Announces Key Research and Development …
Top of page. Our Science. Our ProgramsSee details»
Axial Therapeutics - A Kairos Ventures Portfolio Company
Company Summary. Axial Therapeuticsâ„¢ is a clinical-stage biopharmaceutical company focused on the discovery and development of gut-restricted, small molecule therapeutics for central …See details»
Axial Therapeutics Announces Completion of Enrollment in
Sep 26, 2023 Axial Therapeutics today announced completion of enrollment in the TAPESTRY Autism Study, the Phase 2b clinical trial of its lead product candidate, AB-2004, a first-in-class …See details»
Autism Spectrum Disorder - Axial Therapeutics
Addressing Unmet Medical Needs in Autism Spectrum Disorder According to the Centers for Disease Control and Prevention (CDC), approximately 1 in 36 children under the age of 8 may …See details»
Axial Therapeutics Announces Participation of its CEO, A. Stewart ...
May 2, 2022 Axial Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for neurSee details»
Axial Therapeutics Announces Completion of Enrollment in Global …
Sep 26, 2023 About the AB-2004 Phase 2b Trial The Phase 2b trial is a global, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of AB …See details»
Axial Therapeutics Company Information - Funding, Investors, and …
Key Insights: Axial Biotherapeutics Series C round, October 13, 2021: $37.25m Axial Biotherapeutics funding round, June 2019: $10m Axial Biotherapeutics Venture round, June …See details»
Axial Biotherapeutics - Craft
Axial Biotherapeutics is the latest microbiome firm to emerge. Private and venture capital investors, including Longwood Fund and Domain Associates, have put an initial $19 million …See details»
Axial Therapeutics Announces Age Expansion in Global Phase
Apr 4, 2023 Approximately 1 in 44 children in the U.S. and 1 in 100 children worldwide have been identified with ASD according to the Centers for Disease Control and Prevention (CDC) …See details»
Axial Therapeutics Announces Completion of Enrollment in Global …
Sep 26, 2023 Topline clinical data anticipated in 1Q 2024 First-in-class small molecule therapeutic targets the microbiome gut-brain axis and its role in autism, offering a potential …See details»
Axial Therapeutics Raises $37.25 Million in Series C Financing to ...
Top of page. Our Science. Our ProgramsSee details»
Axial Therapeutics Doses First Subjects in Global Phase 2b Clinical ...
Nov 30, 2021 Axial’s lead product candidate is AB-2004, a molecular therapeutic in Phase 2 clinical trials for the treatment of irritability in children with autism. For more information, visit …See details»
AxialBridge
AxialBridge is a female-led bespoke life sciences advisory firm dedicated to the advancement of novel therapeutics, devices and digital health platforms by providing a more targeted and …See details»
Axial Biotherapeutics Presents New Preclinical Data from AB-2004 ...
May 2, 2019 Preclinical results support development of AB-2004 as potential treatment for gastrointestinal dysfunction and associated behavioral symptoms of Autism Spectrum Disorder …See details»
McKinsey’s LegacyX: Rejuvenating legacy ... - McKinsey & Company
2 days ago March 20, 2025 At the core of virtually every large organization lies an aging digital infrastructure, often slowing down innovation and agility. In fact, 70 percent of the software …See details»
Press Releases - Axial Therapeutics
September 26, 2023. Axial Therapeutics Announces Completion of Enrollment in Global Phase 2b Clinical Trial for AB-2004 for Irritability Associated with AutismSee details»